Oct 2, 2026NeurologyLive
Advancing Women’s Health in Multiple Sclerosis
A discussion with MS researcher Sandra Vukusic, MD, PhD, focused on pregnancy counseling, treatment decisions and overlooked women’s health issues in MS.
Why this matters to youMS disproportionately affects women, often during reproductive years, so women’s health deserves a visible place in MS education.
Read source ↗Sep 30, 2026NeurologyLive
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
The FDA accepted a new drug application for the investigational BTK inhibitor fenebrutinib under priority review for relapsing and primary progressive MS.
Why this matters to youWe’re sharing this as a pipeline update, not a treatment recommendation. Regulatory reviews can change, but this is an important development to follow.
Read source ↗Sep 28, 2026National MS Society
Global Estimate of People Living with MS Reaches 3.1 Million
New Atlas of MS findings estimate about 3.1 million people worldwide are living with MS, with nearly one million in the United States.
Why this matters to youPrevalence data helps explain why access, education and support infrastructure remain so important for the MS community.
Read source ↗Sep 9, 2026American Academy of Neurology
Early MS Treatments Differ Most in Relapses and MRI Lesions, Not Disability
A study of 509 people newly diagnosed with MS found modest differences in relapses and MRI activity across initial treatment approaches after two years, without detected differences in disability scores.
Why this matters to youTreatment decisions are nuanced. This is a good example of why study outcomes, limitations and individual goals all matter in treatment conversations.
Read source ↗